FDA Brief

Warning letters Food

FDA warning letter to

Pharmaganics LLC

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA and FTC warn Pharmaganics over diabetes supplement claims that make unapproved, misbranded drugs.

What happened

In August 2021, FDA reviewed the company’s website, Facebook and Instagram pages, Amazon storefront, and Walmart product listing, and FTC reviewed its websites. The listings claimed the supplements fight insulin resistance, lower blood sugar and A1C, support diabetes organ health, and help prevent or treat type 2 diabetes. FDA determined the products are unapproved new drugs and misbranded, and FTC said the disease claims may lack competent and reliable scientific evidence.

What FDA found

  1. The company’s websites and product listings claimed the supplements prevent, treat, or manage diabetes and blood sugar, so FDA treats them as drugs.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses and lack FDA approval.

    Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded—illegally labeled—because they lack adequate directions for use for diseases that laypeople cannot safely self-treat.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5
  4. Selling the misbranded products in interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]
  5. FTC says diabetes prevention or treatment claims must be backed by competent and reliable scientific evidence, including well-controlled human clinical studies.

    FTC Act, 15 U.S.C. § 41 et seq.
  6. FTC can seek civil penalties for deceptive disease treatment, cure, prevention, or mitigation claims.

    Sections 5(m)(1)(B) and 19(b) of the FTC Act [15 U.S.C. §§ 45(m)(1)(B), 57b(b)]

What FDA wants

FDA asks Pharmaganics to reply in writing within 15 working days describing specific corrective steps, documentation, and how it will prevent recurrence, or explain why more time is needed. FTC separately asks for notice within 15 working days of actions taken to address its concerns.

Who should pay attention

  • dietary supplement brands making diabetes or blood-sugar claims
  • retailers and marketplaces hosting supplement disease claims
  • companies selling supplements through Amazon or Walmart

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk